Semiannual Report — FY2026 H1
What Mochida Pharmaceutical Co.,Ltd. reported for the period from 2026-04-01 to 2026-09-30.
Filed 2026-11-11View the original on EDINET
How much it says
60Detailed
What moved here
13named for the first time
Its own wording
25terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, sales increased in both the pharmaceutical business, driven in part by growth in core products, and the healthcare business. Operating profit, ordinary profit and interim net income attributable to owners of the parent also increased. In addition, the board resolved to assume the marketing approval for Fuji Yakuhin’s Topirolic Tablets and acquire related assets, including intellectual property rights, and the company executed the agreement.
Komori's summary of this document, not the document's own words.60Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
68
Detailed
100
Very detailed
75
Very detailed
0
Almost nothing
68
Detailed
27
Almost nothing
62
Detailed
47
Typical
55
Typical
73
Detailed
R&D spend54億円Money spent making new things.
Cash left over49億円Cash from the business, less what went into equipment.
Spent on equipment6億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.